Skip to content
2000
Volume 23, Issue 12
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Bosentan and its analogues were first reported as endothelin (ET) receptor antagonists in US patent No. 5, 292,740 in 1994. Bosentan synthesis has been reported by employing different methods from the reaction between (4,6-dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidine and 4- (tert-butyl) benzenesulfonamide and 4-(tert-butyl)-N-(6-chloro-5-(2-methoxyphenoxy)-[2,2'- bipyrimidin]-4-yl) benzenesulfonamide in the form of different salts like potassium salt, ammonium salt, sodium salt, and free, on its reaction with ethylene glycol. Several changes have been observed in the chemistry of the involved intermediate synthesis, particularly coupling chemistry, to produce bosentan derivatives with high purity and yield.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557522666220510113702
2023-07-01
2025-11-09
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557522666220510113702
Loading

  • Article Type:
    Review Article
Keyword(s): antagonist; Bosentan; catalysis; endothelin; one-pot; tracleer
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test